The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Acrotech Biopharma; Astellas Pharma; Corcept Therapeutics; Gilead Sciences; Merck; Regenacy Pharmaceuticals
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Forty Seven (Inst); Gritstone Bio (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Advaxis; Amgen; Lilly
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Sandip Pravin Patel
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Compugen; Illumina; Lilly; Nektar; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Theodore Welling
No Relationships to Disclose
 
Maria Pia Morelli
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); AstraZeneca (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Julian R. Molina
No Relationships to Disclose
 
Kedar Kirtane
Stock and Other Ownership Interests - Agenus; Immunomedics; Macrogenics; Myovant Sciences; Oncternal Therapeutics; Seagen; Veru
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Michelle Fan-Port
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Armen Mardiros
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
Patents, Royalties, Other Intellectual Property - MustangBio
 
Karl Beutner
Stock and Other Ownership Interests - Amgen; Tempus
Research Funding - Amgen; Tempus
Travel, Accommodations, Expenses - Tempus
 
Ariane Lozac'hmeur
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Patents, Royalties, Other Intellectual Property - Tempus
 
Denise Lau
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Research Funding - Tempus
Patents, Royalties, Other Intellectual Property - Tempus
Travel, Accommodations, Expenses - Tempus
 
Kirstin B. Liechty
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Judy Vong
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Eric Ng
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen
Travel, Accommodations, Expenses - Amgen
 
David G. Maloney
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Genentech/Roche; Gilead Sciences; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead company; Legend Biotech; MorphoSys; MustangBio; Novartis; Pharmacyclics; Umoja Biopharma
Consulting or Advisory Role - A2 Biotherapeutics; Celgene/Bristol-Myers Squibb; Genentech; NAVAN Technologies
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
William Y. Go
Employment - A2 Biotherapeutics
Leadership - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; A2 Biotherapeutics; Amgen; Gilead Sciences
Research Funding - A2 Biotherapeutics
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - American Pancreatic Association; Viewpoint School
 
Diane M. Simeone
Consulting or Advisory Role - Celgene
Research Funding - Abbvie
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
Travel, Accommodations, Expenses - Konica Minolta Precision Medicine